275 related articles for article (PubMed ID: 15149512)
1. Topical vitamin B12--a new therapeutic approach in atopic dermatitis-evaluation of efficacy and tolerability in a randomized placebo-controlled multicentre clinical trial.
Stücker M; Pieck C; Stoerb C; Niedner R; Hartung J; Altmeyer P
Br J Dermatol; 2004 May; 150(5):977-83. PubMed ID: 15149512
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial.
Stainer R; Matthews S; Arshad SH; McDonald S; Robinson J; Schapira C; Foote KD; Baird-Snell M; Gregory T; Pollock I; Stevens MT; Edwards AM
Br J Dermatol; 2005 Feb; 152(2):334-41. PubMed ID: 15727648
[TBL] [Abstract][Full Text] [Related]
3. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
4. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial.
Hoeger PH; Lee KH; Jautova J; Wohlrab J; Guettner A; Mizutani G; Hultsch T
Br J Dermatol; 2009 Feb; 160(2):415-22. PubMed ID: 19067708
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of a cream containing AR-GG27® (sorbityl furfural palmitate) in the treatment of mild/moderate childhood atopic dermatitis associated with pityriasis alba. A double-blind, placebo-controlled clinical trial.
Patrizi A; Raone B; Raboni R; Neri I
G Ital Dermatol Venereol; 2012 Dec; 147(6 Suppl 1):1-8. PubMed ID: 23007324
[TBL] [Abstract][Full Text] [Related]
6. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial.
Gong JQ; Lin L; Lin T; Hao F; Zeng FQ; Bi ZG; Yi D; Zhao B
Br J Dermatol; 2006 Oct; 155(4):680-7. PubMed ID: 16965415
[TBL] [Abstract][Full Text] [Related]
7. A double-blind study of tolerance and efficacy of a new urea-containing moisturizer in patients with atopic dermatitis.
Bissonnette R; Maari C; Provost N; Bolduc C; Nigen S; Rougier A; Seite S
J Cosmet Dermatol; 2010 Mar; 9(1):16-21. PubMed ID: 20367668
[TBL] [Abstract][Full Text] [Related]
8. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial.
Doss N; Reitamo S; Dubertret L; Fekete GL; Kamoun MR; Lahfa M; Ortonne JP
Br J Dermatol; 2009 Aug; 161(2):427-34. PubMed ID: 19416227
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy and safety of loratadine syrup in childhood atopic dermatitis treated with mometasone furoate 0.1 per cent cream.
Chunharas A; Wisuthsarewong W; Wananukul S; Viravan S
J Med Assoc Thai; 2002 Apr; 85(4):482-7. PubMed ID: 12118496
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
[TBL] [Abstract][Full Text] [Related]
11. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.
Reitamo S; Harper J; Bos JD; Cambazard F; Bruijnzeel-Koomen C; Valk P; Smith C; Moss C; Dobozy A; Palatsi R;
Br J Dermatol; 2004 Mar; 150(3):554-62. PubMed ID: 15030341
[TBL] [Abstract][Full Text] [Related]
12. Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial.
Spergel JM; Boguniewicz M; Paller AS; Hebert AA; Gallagher PR; McCormick C; Parneix-Spake A; Hultsch T
Br J Dermatol; 2007 Aug; 157(2):378-81. PubMed ID: 17573885
[TBL] [Abstract][Full Text] [Related]
13. Treatment of pruritus with topically applied opiate receptor antagonist.
Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M
J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitis.
Herzog JL; Solomon JA; Draelos Z; Fleischer A; Stough D; Wolf DI; Abramovits W; Werschler W; Green E; Duffy M; Rothaul A; Tansley R
J Drugs Dermatol; 2011 Aug; 10(8):853-60. PubMed ID: 21818506
[TBL] [Abstract][Full Text] [Related]
15. A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea.
Karabulut AA; Izol Serel B; Eksioglu HM
J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):729-34. PubMed ID: 18328059
[TBL] [Abstract][Full Text] [Related]
16. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial.
Leung DY; Hanifin JM; Pariser DM; Barber KA; Langley RG; Schlievert PM; Abrams B; Hultsch T
Br J Dermatol; 2009 Aug; 161(2):435-43. PubMed ID: 19416245
[TBL] [Abstract][Full Text] [Related]
17. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial.
Gollnick H; Kaufmann R; Stough D; Heikkila H; Andriano K; Grinienko A; Jimenez P;
Br J Dermatol; 2008 May; 158(5):1083-93. PubMed ID: 18341665
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants.
Ho VC; Gupta A; Kaufmann R; Todd G; Vanaclocha F; Takaoka R; Fölster-Holst R; Potter P; Marshall K; Thurston M; Bush C; Cherill R
J Pediatr; 2003 Feb; 142(2):155-62. PubMed ID: 12584537
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.
Luger TA; Lahfa M; Fölster-Holst R; Gulliver WP; Allen R; Molloy S; Barbier N; Paul C; Bos JD
J Dermatolog Treat; 2004 Jun; 15(3):169-78. PubMed ID: 15204150
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes from a multicenter, randomized, vehicle-controlled clinical study of MAS063DP (Atopiclair) in the management of mild-to-moderate atopic dermatitis in adults.
Abramovits W; Hebert AA; Boguniewicz M; Kempers SE; Tschen E; Jarratt MT; Lucky AW; Cornelison RL; Swinyer LJ; Jones TM
J Dermatolog Treat; 2008; 19(6):327-32. PubMed ID: 18728923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
